Researchers have discovered

new subgroups of stomach cancer patients with different disease characteristics,

information that could help improve the clinical management of a

disease that still kills a dismaying 3 out of 4 patients. 

The study searched for somatic (acquired after birth) abnormalities in the molecule

E-cadherin (an important tumor suppressor), linking these to the patients’ disease

history. The results led to the identification of several GC groups with

different disease characteristics and even survival chances, including one with

the worst prognoses of all. This new information is hoped to be the first step

towards better therapeutic decisions to improve the patients’ quality of life

and maybe even their survival. 

Stomach/gastric

cancer (GC) is the second deadliest

of all cancers, killing 3 quarters of the patients - almost a million people a

year. The problem is that the disease not only tends to show no symptoms until

is too late, but is also very heterogeneous. What this means is that apparently

similar patients can have very different outcomes, making GC not only very

lethal but also of difficult clinical management.

 And even if researchers have

discovered much about the disease’s triggers and molecular abnormalities, the

information often has not been linked to the clinical side of GC, giving it limited

value for patient’s everyday care.

Endoscopic image of a early stomach cancer, by Med Chaos   

In an attempt to address these problems, the study searched for somatic abnormalities

in E-cadherin, but correlating these with the patients’ disease history. Somatic abnormalities refer to genetic

changes that occur after birth, in opposition to inherited abnormalities, which are present at birth. Inherited abnormalities

in E-cadherin are the most important cause of hereditary GC, thus  the choice of

this molecule for the new study.

The work used patients with no inherited E-cadherin abnormalities and from

all types of GC. In fact, GC can be classified according to cancer morphology, behavior,

inheritance and disease manifestation. So, we can have intestinal gastric cancer (when cancer masses develop in the

stomach) versus diffuse GC (when there

are, instead, invading individual cancerous cells, a type that normally carries

worse diagnosis).

In terms of occurrence, the disease can be sporadic (when there is no other cases

in the family), hereditary (when it

exists in the family and the reason is inherited) or familial (if it runs in

the family due to some degree of susceptibility combined with non-genetic

causes, like for example, eating habits).

In the new work, the researchers started by looking for

E-cadherin somatic changes in all GC patients. Remarkably, it was found that as much as a third of patients had them. The patients were

then divided in 3 groups: those with no changes in E-cadherin, those with structural changes (when there are abnormalities

in the E-cadherin chromosome itself) and finally those patients with functional

alterations but an intact chromosomal structure.

These new groups

showed different patterns of disease what is extremely promising for the development

of therapies and needs to be further investigated.

The most

interesting finding, though, was that patients with structural abnormalities

had the worse prognoses, especially those presenting familial intestinal GC – none of them

surviving more than 5 years after removal of the tumor. This is not only

important because it marks these patients as those that need more radical and

urgent care, but also because the current paradigm is that intestinal tumors have

the best survival chance. 

 Also interesting was the discovery that individuals

with functional anomalies often had diffuse GC with metastases in the lymph

node. This suggests that once this abnormality is detected nodes’ removal

should be a priority to stop disease from spreading.

Their work reveals how different abnormalities in

E-cadherin are linked to different types of gastric cancer. Although the

results need to be reproduced and better understood, this is an important first

step to improve patients’ management in clinic, particularly to infer the

prognosis of GC and the pattern of tumour dissemination, and from that, make

the best possible decisions to improve patients’ quality of life and even

survival. 

Citation:

Giovanni

Corso, Joana Carvalho, Daniele Marrelli, Carla Vindigni, Beatriz Carvalho,

Raquel Seruca, Franco Roviello, and Carla Oliveira , 'Somatic Mutations and Deletions of the

E-Cadherin GenePredict Poor Survival of Patients With Gastric Cancer', Journal of Clinical Oncology, published online before print January 22, 2013, doi: 10.1200/JCO.2012.44.4612